Israeli medtech company CartiHeal to be acquired for $500 million by Bioventus

CartiHeal was founded at Peregrine's Incubator back in 2009 as a joint venture with the Ben Gurion university

Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Medtech company CartiHeal is being acquired by Nasdaq-traded Bioventus for a sum estimated at $500 million. Bioventus announced on Monday that it has elected to make a $50 million escrow payment pursuant to its option and equity purchase agreement with CartiHeal signed last year, signaling its intent to move forward with an acquisition of the Kfar Saba-based company. Bioventus said that its decision came following its review of a "statistical analysis report of the pivotal clinical trial of the Agili-C implant, reimbursement coding analysis, and significant market diligence including surgeon interviews with respect to Agili-C’s commercialization opportunity and ultimate market potential."

Tou can read more here and here